JP2021530487A5 - - Google Patents
Info
- Publication number
- JP2021530487A5 JP2021530487A5 JP2021500587A JP2021500587A JP2021530487A5 JP 2021530487 A5 JP2021530487 A5 JP 2021530487A5 JP 2021500587 A JP2021500587 A JP 2021500587A JP 2021500587 A JP2021500587 A JP 2021500587A JP 2021530487 A5 JP2021530487 A5 JP 2021530487A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- pharmaceutically acceptable
- group
- compounds selected
- acceptable salt
- Prior art date
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862696440P | 2018-07-11 | 2018-07-11 | |
| US62/696,440 | 2018-07-11 | ||
| US201862737250P | 2018-09-27 | 2018-09-27 | |
| US62/737,250 | 2018-09-27 | ||
| US201962834525P | 2019-04-16 | 2019-04-16 | |
| US62/834,525 | 2019-04-16 | ||
| PCT/US2019/041351 WO2020014445A1 (en) | 2018-07-11 | 2019-07-11 | Ep4 inhibitors and synthesis thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021530487A JP2021530487A (ja) | 2021-11-11 |
| JP2021530487A5 true JP2021530487A5 (https=) | 2022-07-20 |
| JPWO2020014445A5 JPWO2020014445A5 (https=) | 2022-07-20 |
Family
ID=69141735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021500587A Pending JP2021530487A (ja) | 2018-07-11 | 2019-07-11 | Ｅｐ４阻害剤およびその合成 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20210300921A1 (https=) |
| EP (1) | EP3820469A4 (https=) |
| JP (1) | JP2021530487A (https=) |
| CN (1) | CN113301896A (https=) |
| CA (1) | CA3107023A1 (https=) |
| IL (1) | IL280051B2 (https=) |
| WO (1) | WO2020014445A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10973834B2 (en) | 2018-04-16 | 2021-04-13 | Arrys Therapeutics, Inc. | EP4 inhibitors and use thereof |
| US20210315909A1 (en) | 2018-07-11 | 2021-10-14 | Arrys Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| US11254675B2 (en) * | 2019-08-12 | 2022-02-22 | Cadila Healthcare Limited | Process for preparation of grapiprant |
| CN110386941A (zh) * | 2019-08-15 | 2019-10-29 | 上海邦耀生物科技有限公司 | Ep4受体拮抗剂和pd-1抑制剂联合用于癌症的治疗 |
| CN115697317A (zh) * | 2020-04-08 | 2023-02-03 | 株式会社AskAt | Ep4受体拮抗剂用于治疗肝癌、黑色素瘤、淋巴瘤和白血病的应用 |
| TWI877433B (zh) * | 2020-11-30 | 2025-03-21 | 大陸商杭州阿諾生物醫藥科技有限公司 | 用於治療ｐｉｋ３ｃａ突變癌症的組合療法 |
| CN117377471A (zh) * | 2021-05-28 | 2024-01-09 | 凯复(苏州)生物医药有限公司 | 治疗肿瘤的联合疗法 |
| US20240343725A1 (en) * | 2021-08-01 | 2024-10-17 | Zenfold Sustainable Technologies Private Limited | A process for the preparation of grapiprant and its intermediates |
| CN117466888A (zh) * | 2023-10-30 | 2024-01-30 | 西北农林科技大学 | 一种1h-咪唑并[4,5-c]吡啶化合物的制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HN2001000224A (es) * | 2000-10-19 | 2002-06-13 | Pfizer | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos. |
| CN1867551B (zh) * | 2003-09-03 | 2013-09-11 | 拉夸里亚创药株式会社 | 作为前列腺素e2拮抗剂的苯基或吡啶基酰胺化合物 |
| EP1740211A2 (en) * | 2004-04-20 | 2007-01-10 | Pfizer Products Incorporated | Combinations comprising alpha-2-delta ligands and ep4 receptor antagonists |
| CN101137656B (zh) * | 2005-03-11 | 2010-12-22 | 拉夸里亚创药株式会社 | 咪唑衍生物的晶型 |
| EP3431085B1 (en) * | 2009-04-22 | 2023-10-11 | AskAt Inc. | Selective ep4 receptor antagonistic substance for treatment of cancer |
| UA115576C2 (uk) * | 2012-12-06 | 2017-11-27 | Байєр Фарма Акцієнгезелльшафт | Похідні бензимідазолу як антагоністи ер4 |
| NZ733234A (en) * | 2014-03-06 | 2018-08-31 | Aratana Therapeutics Inc | Crystalline forms of grapiprant |
| US10342785B2 (en) * | 2016-11-04 | 2019-07-09 | Askat Inc. | Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer |
-
2019
- 2019-07-11 EP EP19835062.1A patent/EP3820469A4/en not_active Withdrawn
- 2019-07-11 US US17/258,527 patent/US20210300921A1/en not_active Abandoned
- 2019-07-11 JP JP2021500587A patent/JP2021530487A/ja active Pending
- 2019-07-11 WO PCT/US2019/041351 patent/WO2020014445A1/en not_active Ceased
- 2019-07-11 IL IL280051A patent/IL280051B2/en unknown
- 2019-07-11 CA CA3107023A patent/CA3107023A1/en active Pending
- 2019-07-11 CN CN201980056154.3A patent/CN113301896A/zh active Pending
-
2023
- 2023-12-13 US US18/538,687 patent/US20240254120A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021530487A5 (https=) | ||
| JP2021530451A5 (https=) | ||
| EP3704096B1 (en) | Modulators of the integrated stress pathway | |
| KR20180116307A (ko) | Prmt5 저해제로 사용하기 위한 치환 뉴클레오사이드 유사체 | |
| JP2020506951A5 (https=) | ||
| JP2011509949A5 (https=) | ||
| JP2011500758A5 (https=) | ||
| JP2020511512A5 (https=) | ||
| JPWO2020006264A5 (https=) | ||
| JP2012524731A5 (https=) | ||
| JP2008535902A5 (https=) | ||
| JP2008510770A5 (https=) | ||
| JP2019501204A5 (https=) | ||
| JP2014500870A5 (https=) | ||
| HU229076B1 (en) | Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties | |
| JP2017510610A5 (https=) | ||
| JP2008535903A5 (https=) | ||
| EP3171870B1 (en) | Protein phosphatase 2a inhibitors for treating myelodysplastic syndromes | |
| JP2011526917A5 (https=) | ||
| JP2016513696A5 (https=) | ||
| JP2021530444A5 (https=) | ||
| JPWO2020014445A5 (https=) | ||
| US12599603B2 (en) | Methods of treatment | |
| JP2024125139A5 (https=) | ||
| JP2017503016A5 (https=) |